Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval. Roche has previously priced drugs at a sharp discount to hurt sales for Biogen and also hopes to show "unequivocal data on efficacy" for gantenerumab, in stark contrast to the controversy over Aduhelm's efficacy.

Continue reading

Source Fool.com